Skip to main content
SpringerLink
Log in

Effects of fluticasone plus salmeterol versus twice the dose of fluticasone in asthmatic patients

  • Pharmacodynamics
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Objective

Current guidelines advocate adding a long acting β2-agonist (LABA) to an inhaled corticosteroid as an alternative to increasing the dose of the latter. Since it is unclear how this translates into effects on surrogate inflammatory markers, we evaluated the anti-inflammatory activity of fluticasone plus salmeterol in combination versus twice the dose of fluticasone alone.

Methods

Fifteen mild-to-moderate asthmatics (mean FEV1 80% predicted) uncontrolled on inhaled corticosteroids (mean dose 470 μg) were randomised in a single-blind crossover fashion to receive 2 weeks each of fluticasone 250 µg plus salmeterol 50 µg in combination (FP+SM), 1 puff b.i.d., and fluticasone 500 µg (FP), 1 puff b.i.d. Prior to each randomised treatment, there was a 2-week run-in and washout period during which patients used their usual inhaled corticosteroid therapy. Measurements were made before and after randomised treatment periods. The primary outcome was airway hyper-responsiveness to adenosine monophosphate (AMP PC20), while secondary endpoints were exhaled tidal nitric oxide (NO), forced expiratory volume in 1 second (FEV1) and forced mid-expiratory flow (FEF25–75).

Results

For AMP PC20, FP alone but not FP+SM conferred a significant (P<0.05) improvement amounting to 3.27 (95% CI 1.46–7.32) and 1.44 (95% CI 0.64–3.23) geometric mean fold shifts, respectively, from baseline, while the difference between treatments was significantly (P<0.05) greater with FP alone: a 2.26-fold (95% CI 1.01–5.07) difference. Both FP alone and FP+SM conferred significant (P<0.05) falls in NO from baseline: 2.33 (95% CI 1.71–3.19) and 1.49 (95% CI 1.09–2.03) geometric mean fold changes, respectively, while between treatments the reduction was significantly (P<0.05) greater with FP alone: a 1.57-fold (95% CI 1.15–2.14) difference. Neither treatment significantly improved FEV1 or FEF25–75.

Conclusion

Double the dose of FP alone relative to FP+SM conferred superior effects on surrogate inflammatory markers but not on lung function. Long-term studies are required to evaluate whether these improvements on surrogate inflammatory markers translate into commensurate reductions in airway remodelling and exacerbations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.

Similar content being viewed by others

References

  1. Anonymous (1997) The British Thoracic Society guidelines on asthma management: 1995 review and position statement. Thorax 52[Suppl 1]:S1–S21

  2. National Institutes of Health (1997) National Asthma Education and Prevention Program. Expert Panel Report 2. Guidelines for the diagnosis and management of asthma, publication no. 97–4051. Bethesda, MD

  3. Lipworth BJ (1999) Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med 159:941–955

    Google Scholar 

  4. Eickelberg O, Roth M, Lorx R, Bruce V, Rudiger J, Johnson M, Block LH (1999) Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J Biol Chem 274:1005–1010

    Article  CAS  PubMed  Google Scholar 

  5. Roth M, Johnson PR, Rudiger JJ, King GG, Ge Q, Burgess JK, Anderson G, Tamm M, Black JL (2002) Interaction between glucocorticoids and beta2-agonists on bronchial airway smooth muscle cells through synchronised cellular signalling. Lancet 360:1293–1299

    Article  CAS  PubMed  Google Scholar 

  6. Shrewsbury S, Pyke S, Britton M (2000) Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ 320:1368–1373

    Article  CAS  PubMed  Google Scholar 

  7. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, Runnerstrom E, Sandstrom T, Svensson K, Tattersfield A (2001) Low-dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 164:1392–1397

    CAS  PubMed  Google Scholar 

  8. Crapo RO, Casaburi R, Coates AL, Enright PL, Hankinson JL, Irvin CG, MacIntyre NR, McKay RT, Wanger JS, Anderson SD, Cockcroft DW, Fish JE, Sterk PJ (2000) Guidelines for methacholine and exercise challenge testing—1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med 161:309–329

    CAS  PubMed  Google Scholar 

  9. Kharitonov SA, Alving K, Barnes PJ (1997) Exhaled and nasal nitric oxide measurements: recommendations. The European Respiratory Society Task Force. Eur Respir J 10:1683–1693

    CAS  PubMed  Google Scholar 

  10. American Thoracic Society (1995) Standardization of spirometry, 1994 update. Am J Respir Crit Care Med 152:1107–1136

    PubMed  Google Scholar 

  11. Tan KS, McFarlane LC, Lipworth BJ (1997) Loss of normal cyclical beta2–adrenoceptor regulation and increased premenstrual responsiveness to adenosine monophosphate in stable female asthmatic patients. Thorax 52:608–611

    CAS  PubMed  Google Scholar 

  12. Ward C, Pais M, Bish R, Reid D, Feltis B, Johns D, Walters EH (2002) Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma. Thorax 57:309–316

    Article  CAS  PubMed  Google Scholar 

  13. Reddel HK, Jenkins CR, Marks GB, Ware SI, Xuan W, Salome CM, Badcock CA, Woolcock AJ (2000). Optimal asthma control, starting with high doses of inhaled budesonide. Eur Respir J 16:226–235

    Article  CAS  PubMed  Google Scholar 

  14. Vignola AM, Chanez P, Campbell AM, Souques F, Lebel B, Enander I, Bousquet J (1998) Airway inflammation in mild intermittent and in persistent asthma. Am J Respir Crit Care Med 157:403–409

    CAS  PubMed  Google Scholar 

  15. Boulet LP, Turcotte H, Brochu A (1994) Persistence of airway obstruction and hyperresponsiveness in subjects with asthma remission. Chest 105:1024–1031

    CAS  PubMed  Google Scholar 

  16. Holt S, Suder A, Weatherall M, Cheng S, Shirtcliffe P, Beasley R (2001) Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis. BMJ 323:253–256

    Article  CAS  PubMed  Google Scholar 

  17. Currie GP, Fowler SJ, Lipworth BJ (2003) Dose–response effect of inhaled corticosteroids: a meta-analysis. Ann Asthma Allergy Immunol 90:194–198

    Google Scholar 

  18. Sont JK, Willems LN, Bel EH, van Krieken JH, Vandenbroucke JP, Sterk PJ (1999) Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. Am J Respir Crit Care Med 159:1043–1051

    PubMed  Google Scholar 

  19. Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, Ullman A (1997) Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 337:1405–1411

    Article  CAS  PubMed  Google Scholar 

  20. Aziz I, Wilson AM, Lipworth BJ (2000) Effects of once-daily formoterol and budesonide given alone or in combination on surrogate inflammatory markers in asthmatic adults. Chest 118:1049–1058

    CAS  PubMed  Google Scholar 

  21. Polosa R, Holgate ST (1997) Adenosine bronchoprovocation: a promising marker of allergic inflammation in asthma? Thorax 52:919–923

    CAS  PubMed  Google Scholar 

  22. Polosa R, Rorke S, Holgate ST (2002) Evolving concepts on the value of adenosine hyperresponsiveness in asthma and chronic obstructive pulmonary disease. Thorax 57:649–654

    Article  CAS  PubMed  Google Scholar 

  23. Van Den Berge M, Meijer RJ, Kerstjens HA, de Reus DM, Koeter GH, Kauffman HF, Postma DS (2001) PC(20) adenosine 5'-monophosphate is more closely associated with airway inflammation in asthma than PC(20) methacholine. Am J Respir Crit Care Med 163:1546–1550

    PubMed  Google Scholar 

  24. Wilson AM, Lipworth BJ (2000) Dose-response evaluation of the therapeutic index for inhaled budesonide in patients with mild-to-moderate asthma. Am J Med 108:269–275

    Article  CAS  PubMed  Google Scholar 

  25. O'Connor BJ, Ridge SM, Barnes PJ, Fuller RW (1992) Greater effect of inhaled budesonide on adenosine 5'-monophosphate-induced than on sodium-metabisulfite-induced bronchoconstriction in asthma. Am Rev Respir Dis 146:560–564

    CAS  PubMed  Google Scholar 

  26. De Meer G, Heederik D, Postma DS (2002) Bronchial responsiveness to adenosine 5'-monophosphate (AMP) and methacholine differ in their relationship with airway allergy and baseline FEV(1). Am J Respir Crit Care Med 165:327–331

    PubMed  Google Scholar 

  27. Dempsey OJ, Kennedy G, Lipworth BJ (2002) Comparative efficacy and anti-inflammatory profile of once-daily therapy with leukotriene antagonist or low-dose inhaled corticosteroid in patients with mild persistent asthma. J Allergy Clin Immunol 109:68–74

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported by an unrestricted University of Dundee departmental grant.

Author information

Authors and Affiliations

  1. Asthma and Allergy Research Group, Ninewells Hospital and Medical School, University of Dundee, DD1 9SY, Dundee, Scotland, UK

    Graeme P. Currie, Caroline E. Bates, Daniel K. C. Lee, Catherine M. Jackson & Brian J. Lipworth

Authors
  1. Graeme P. Currie
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Caroline E. Bates
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daniel K. C. Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Catherine M. Jackson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Brian J. Lipworth
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Brian J. Lipworth.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Currie, G.P., Bates, C.E., Lee, D.K.C. et al. Effects of fluticasone plus salmeterol versus twice the dose of fluticasone in asthmatic patients. Eur J Clin Pharmacol 59, 11–15 (2003). https://doi.org/10.1007/s00228-003-0571-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-003-0571-9

Keywords

Search

Navigation